DHCNI — Diversified Healthcare Trust -

Summary of DHCNI Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Normalized Funds from Operations (FFO): $33.1 million, or $0.14 per share, exceeding analyst expectations.
• Adjusted EBITDAre: $74 million, also above consensus estimates.
• Consolidated Net Operating Income (NOI): Increased 4.7% year-over-year to $75.9 million.
• Same-Property SHOP NOI: Rose 13.5% year-over-year to $44.3 million, with occupancy growth of 110 basis points and average monthly rate growth of 5.9%.
• Same-Property Cash Basis NOI: Increased 8.6% year-over-year.
• General and Administrative (G&A) Expenses: Included $6.6 million in incentive management fees; excluding this, G&A would have been $7.4 million.

2. Strategic Updates and Business Highlights

• DHC is focused on enhancing operational performance through active asset management and partnerships with new operators, yielding positive results in both revenue and expense management.
• The company is targeting capital deployment into high-return projects, specifically converting underutilized skilled nursing wings into independent living or assisted living units, with an initial investment of approximately $20 million expected to add 150 units.
• The medical office and life science portfolio showed solid performance with same-property occupancy increasing to 95.3% and NOI rising 3.7% year-over-year.

3. Forward Guidance and Outlook

• DHC reaffirmed its 2026 guidance for:
  • SHOP NOI: $175 million to $185 million
  • Medical Office and Life Science NOI: $94 million to $98 million
  • Adjusted EBITDAre: $290 million to $305 million
  • Normalized FFO: $0.52 to $0.58 per share
• The company expects continued growth in SHOP NOI driven by improved expense management and operational efficiencies.

4. Bad News, Challenges, or Points of Concern

• Same-property occupancy in the SHOP segment remained flat quarter-over-quarter, attributed to seasonality and ongoing operator transitions, which may hinder growth in the short term.
• Approximately 9% of annualized rental income in the medical office and life science segment is set to expire through 2026, with a portion expected to vacate.
• The company acknowledged potential fluctuations in G&A expenses due to the performance-based management fees, which could impact overall profitability.

5. Notable Q&A Insights

• Management confirmed that the recurring CapEx guidance includes both maintenance and refresh capital, with expectations for a modest reduction in maintenance costs moving forward.
• The focus for new investments will primarily be on renovations rather than acquisitions, leveraging existing portfolio opportunities.
• The transition from AlerisLife is progressing well, with incremental benefits expected as new operators continue to optimize operations.
• Management is optimistic about achieving the SHOP NOI growth targets despite the flat occupancy in Q1, citing a strong pipeline of opportunities and improved operational strategies.

Overall, DHC reported a strong first quarter with positive financial metrics and strategic initiatives aimed at long-term growth, although challenges in occupancy and potential fluctuations in expenses remain areas to monitor.